Why is "Leo Pharma" trending?
Latest news, Wikipedia summary, and trend analysis.
Trend Analysis
- Ranking position: #
- Date: 2026-08-11 11:46:02
This topic has appeared in the trending rankings 1 time(s) in the past year. While it does not trend frequently, its appearance suggests a renewed or concentrated surge of public interest.
Based on Wikipedia pageviews and search interest, this topic gained significant attention on the selected date.
Trend Insight
Leo_Pharma entered the ranking for the first time today at position #. This is its highest position ever recorded.
Trend History
This topic has appeared in the English Wikipedia rankings 1 time. It first appeared on 2026-08-11 and was most recently seen on 2026-08-11.
Wikipedia Overview
LEO Pharma A/S is a multinational Danish pharmaceutical company, founded in 1908, with a presence in about 100 countries. Its headquarters are in Ballerup, near Copenhagen The company is 100% integrated into a private foundation owned by the LEO Foundation. LEO Pharma develops and markets products for dermatology, bone remodeling thrombosis and coagulation. In 1945, it was the first producer of penicillin outside the US and UK.
Read more on Wikipedia →Related Topics
Trending Topic Today
Search Interest Perspective
-
Leo Pharma pays $50M for Replay and its preclinical skin disease gene therapy - Fierce Biotech
-
Analyst on Leo Pharma's operations in Russia: Bad for reputation - medwatch.com
-
LEO Pharma to acquire gene therapy company Replay - Pharmaceutical Technology
-
JPM26: Leo Pharma’s growth strategy puts a spotlight on rare dermatology diseases - Clinical Trials Arena
-
LEO Pharma to buy U.S. drug developer Replay for $50 million upfront - Reuters
-
Latham & Watkins Advises LEO Pharma in Acquisition of Replay Gene Therapy Platform - Latham & Watkins LLP
-
Leo Pharma Eyes $800 Million Deal Push as IPO Plans Advance - Bloomberg.com
-
JPM26: Leo Pharma, hungry for more partnerships, looks to widen reach in rare dermatology diseases - fiercepharma.com
-
LEO Pharma to Showcase New Data Highlighting the Burden and Unmet Needs in Chronic Hand Eczema at ESCD 2026 in Copenhagen - Yahoo Finance
-
LEO Pharma Delivers 9% Revenue Growth at CER in Q1 2026 and Strengthens Innovation Pipeline - Business Wire
-
LEO Pharma Expands Adtralza to Younger Children - AllSci
-
LEO Pharma Finalizes Acquisition of Spesolimab for GPP - Dermatology Times
-
“It’s GO time”: LEO Pharma launches Direct-to-Consumer campaign to raise awareness of Chronic Hand Eczema - BioSpace
-
Summer series: Leo Pharma's CEO considers China's role in the life sciences to be “difficult to overestimate” - medwatch.com
-
Danish Drugmaker Leo Pharma Is Said to Seek Bank Pitches for IPO - Bloomberg.com
-
Leo Pharma's Russian operations could pose a challenge to its IPO plans - medwatch.com
-
Leo Pharma Is Said to Add More Banks to Copenhagen IPO Lineup - Bloomberg.com
-
Leo Pharma climbs up from bottom ranks but remains among companies with worst reputations - medwatch.com
-
Drugmaker Leo Pharma Is Said to Pick Banks for Copenhagen IPO - Bloomberg.com
-
Leo Pharma owner expresses interest in new investment opportunities - medwatch.com
-
In new deal, pharma company acquires DEB gene therapy developer - epidermolysisbullosanews.com
-
LEO Pharma Delivers 10% Revenue Growth in 2025 and More Than Doubles Adjusted EBITDA Margin - Business Wire
-
When Christophe Bourdon took over as CEO of Leo Pharma, tragedy struck: "You realize how brutal life can be" - medwatch.com
-
LEO Pharma bolsters rare skin disease focus by acquisition of Replay - EMJ
-
Leo Pharma monitors situation in Middle East - medwatch.com
-
LEO Pharma acquires Replay for $50m - EMJ
-
Er-Kim Signs Exclusive Distribution Agreement with LEO - GlobeNewswire
-
Leo Pharma acquires US biotech company Replay - medwatch.com
-
LEO Pharma to acquire Replay gene therapy platform - PMLiVE
-
LEO Pharma launches DTC campaign for Anzupgo to tackle chronic hand eczema misconceptions - Medical Marketing and Media
-
LEO Pharma Presents New 12-Month Real-World Data for Tralokinumab at AAD 2026 - BioSpace
-
Leo roars onto Netflix with DTC campaign for new hand eczema cream Anzupgo - fiercepharma.com
-
LEO Pharma and Allergy UK launch ‘Don’t Ignore’ chronic hand eczema campaign - PMLiVE
-
Phase 3 Setback for TMB-001 Spurs Hopeful Out-Licensing of Vehicle in Congenital Ichthyosis - Dermatology Times
-
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS) - BioSpace
-
LEO Pharma Presents Late-Breaking Results on Temtokibart for Atopic Dermatitis at EADV - Dermatology Times
-
LEO Launches “It’s GO Time” Campaign to Raise Awareness of CHE - The Dermatology Digest
-
Targeting IL-22 in AD: A Q&A About LEO Pharma’s Temtokibart With Michael Ardern-Jones - The Dermatology Digest
-
Leo Pharma says it’s turned a profit for the first time in seven years - Endpoints News
-
LEO Pharma Submits Label-Expansion Application to EMA for Delgocitinib Cream in Teens With CHE - The Dermatology Digest
-
LEO Pharma’s Anzupgo cream progresses to phase 3 trial for lichen sclerosus - PMLiVE
-
C-suite News: Sophie Lamle Named New Chief Development Officer at LEO Pharma - The Dermatology Digest
-
LEO Pharma Reinforces Leadership in Medical Dermatology with New Data from Across Its Portfolio at 2025 Fall Clinical Dermatology Conference - BioSpace
-
LEO Pharma Submits Adolescent Label Expansion Application for Anzupgo® to EMA - BioSpace
-
Media: Leo Pharma advances IPO preparations with bank appointments - medwatch.com
-
Media: Leo Pharma has invited banks to bid on a potential IPO - medwatch.com
-
Former Leo Pharma boss steps down as CEO of Newbury Pharmaceuticals - medwatch.com
-
Leo Pharma taps Amgen executive as new SVP of Global Product Strategy - medwatch.com
-
LEO Pharma’s ‘It’s GO Time’ Gives Chronic Hand Eczema a Voice - Little Black Book | LBBOnline
-
Leo Pharma expects margin shortfall, owners maintain 2026 IPO ambitions - medwatch.com
-
LEO Pharma acquires Spevigo rights, completes dermatology portfolio in Korea - koreabiomed.com
-
Matt Ferriday announced as General Manager for LEO Pharma UK - PMLiVE
-
LEO Pharma Closes Deal for Spevigo® - BioSpace
-
FDA Accepts sNDA for Delgocitinib Cream to Treat Pediatric Chronic Hand Eczema - Dermatology Times
-
LEO Pharma Korea launches Anzupgo Cream for chronic hand eczema - koreabiomed.com
-
LEO Pharma receives NICE approval for chronic hand eczema cream - PMLiVE
-
Leo Pharma seeks approval for key growth hope in China - medwatch.com
-
Delgocitinib Advances to Phase 3 Evaluation for Lichen Sclerosus - Dermatology Times
-
Done Deal: LEO Pharma Closes Deal for BI’s Spesolimab (Spevigo) - The Dermatology Digest
-
LEO Pharma applies to EMA to expand Anzupgo use to adolescents - Pharmaceutical Technology
-
Leo Pharma’s CHE Cream Now Available in the U.S. - The Dermatology Digest
-
EADV 2025 News: Delgocitinib Cream (Anzupgo, LEO Pharma) Performs Well in Adolescents With Moderate-to-Severe CHE - The Dermatology Digest
-
LEO Pharma Presents Late-Breaking Data at EADV 2025 Showing Week 16 Tralokinumab Response Predicts Long-Term Response in Moderate-to-Severe Atopic Dermatitis - BioSpace
-
Leo Pharma secures another approval for key growth hope - medwatch.com
-
LEO Pharma appoints Matt Ferriday as new General Manager - Pf Media
-
Tralokinumab Shows Durable Efficacy and Safety Through 32 Weeks in Phase 3b ADHAND Trial - Dermatology Times
-
Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
-
LEO Pharma Presents Late-Breaking Phase 3 Delgocitinib Cream Data in Adolescents with Moderate to Severe Chronic Hand Eczema (CHE) - BioSpace
-
LEO Pharma secures NICE approval for Anzupgo - The Pharma Letter
-
LEO Pharma advances Anzupgo® (delgocitinib) cream to phase 3 trial in lichen sclerosus (LS) - Via Ritzau
-
Tralokinumab in Moderate-to-Severe Atopic Dermatitis: The Latest Data - EMJ
-
LEO Pharma announces FDA Acceptance of supplemental NDA for ANZUPGO® (delgocitinib) cream for the treatment of Chronic Hand Eczema in children aged 12-17 - Via Ritzau
-
The Future of Atopic Dermatitis Treatment: The Latest Patient Outcomes - EMJ
-
Emirates Dermatology Society and LEO Pharma sign MoU to advance chronic hand eczema awareness in UAE - Gulf News
-
Leo Pharma is one step closer to its 2025-goal – CEO sees no obstacles on the road to the stock market - medwatch.com
-
LEO Pharma expands its psoriasis portfolio in China with NMPA approval of Enstilar® - Via Ritzau
-
LEO Pharma and ICON partner for clinical trial execution in dermatology - Clinical Trials Arena
-
Leo Pharma seeks new acquisitions in rare dermatology - Biostock
-
Leo posts strong sales growth in US, with more to come from hand eczema drug Anzupgo - fiercepharma.com
-
Emirates Dermatology Society and LEO Pharma sign MoU to advance Chronic Hand Eczema awareness in UAE - Zawya
-
Latham & Watkins Advises LEO Pharma in Strategic Partnership With Gilead Sciences - Latham & Watkins LLP
-
Leo Pharma’s Timber bet falls flat following Phase III failure - Clinical Trials Arena
-
FDA Approves LEO Pharma's Delgocitinib for Adults With Moderate to Severe Chronic Hand Eczema - Dermatology Times
-
LEO Pharma secures rights to Boehringer’s Spevigo for $105m - Pharmaceutical Technology
-
Addressing Unmet Needs Globally: LEO Pharma’s Commitment to Dermatology - Dermatology Times
-
Journal of the European Academy of Dermatology and Venereology - Wiley Online Library
-
LEO Pharma reports outcomes from Phase IIb trial of atopic dermatitis therapy - Clinical Trials Arena
-
Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple Inflammatory Diseases - Business Wire
-
Gilead roars into JPM25, inking $1.7B inflammation deal with Leo Pharma - Fierce Biotech
-
LEO Pharma and Gilead Will Develop STAT6 Program for AD and Other Inflammatory Diseases - Dermatology Times
-
LEO Pharma bets on AI to find the next skin-care breakthrough - Computing UK
-
LEO Pharma Reports Positive Results in Delgocitinib Trial for CHE - Dermatology Times
-
Leo Pharma unveils up to 250 layoffs and relocations amid CEO's revamp - fiercepharma.com
-
LEO Pharma to market Junshi's PD-1 inhibitor Loqtorzi in Europe - FirstWord Pharma
-
Leo Pharma’s Timber bet falls flat following Phase III failure - Pharmaceutical Technology
-
Leo roars to key FDA nod for Anzupgo to treat chronic hand eczema - fiercepharma.com
-
Vivian to represent LEO Pharma - Times of Malta
-
LEO Pharma and Boehringer Ingelheim agree on $105 million deal for generalized pustular psoriasis (GPP) treatment Spevigo - Pharmaceutical Executive
-
LEO Pharma Takes Over Global Development of Spevigo for Rare Skin Disease GPP - BioPharm International
-
After transformation under new CEO, Leo Pharma touts innovation model and financial progress - fiercepharma.com
Why This Topic Is Trending
This topic has recently gained attention due to increased public interest. Search activity and Wikipedia pageviews suggest growing global engagement.
Search Interest & Related Topics
Search interest data over the past 12 months indicates that this topic periodically attracts global attention. Sudden spikes often correlate with major news events, public statements, or geopolitical developments.